Lnc000727 promotes differentiation of human bone marrow mesenchymal stem cells into osteoblasts

doi:10.16352/j.issn.1001-6325.2022.07.1047

Abstract

Abstract: Objective To explore the effect of lnc000727 on the differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs) into osteoblasts. Methods Real-time fluorescent quantitative PCR (RT-qPCR) was used to detect the expression of lnc000727. The alkaline phosphatase (ALP) method was used to determine the differentiation of osteoblasts. The expression of lnc000727 in hBM-MSCs was over-expressed or inhibited by liposome transfection. The osteogenic differentiation markers Runt-related transcription factor 2 (RUNX2), osteocalcin (OCN), and pontin were detected by RT-qPCR and Western blot. Pontin (OPN) mRNA and protein expression. The expression of key proteins in the Wnt/β-catenin pathway was analyzed. Results During the differentiation of hBM-MSCs osteoblasts, the expression of lnc000727 and ALP activity increased significantly(P＜0.05). Inhibition of lnc000727 could down-regulate ALP activity and inhibit the expression of osteogenic differentiation markers RUNX2, OCN, OPN and the expression of Wnt and β-catenin (P＜0.05); over-expression of lnc000727 could up-regulate ALP activity and promote the expressions of osteogenic differentiation markers RUNX2, OCN and OPN, and the expressions of Wnt and β-catenin (P＜0.05). Conclusions Lnc000727 promotes the differentiation of hBM-MSCs into osteoblasts, thereby inhibits the occurrence and development of osteoporosis.

Key words: lnc000727, osteoblast differentiation, Wnt/β-catenin signaling pathway, osteoporosis

CLC Number:

PU Chao, ZHANG Shan-shan, WU Qing-xia, LUO Xu-wei, WANG Liang, ZHANG Bo. Lnc000727 promotes differentiation of human bone marrow mesenchymal stem cells into osteoblasts[J]. Basic & Clinical Medicine, 2022, 42(7): 1047-1052.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.07.1047

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I7/1047

References 13

[1]	Macías I, Alcorta-Sevillano N, Rodríguez CI, et al. Osteoporosis and the potential of cell-based therapeutic strategies[J]. Int J Mol Sci, 2020, 21:1653-1676.
[2]	Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors[J]. Nat Rev Rheumatol, 2020, 16:380-390.
[3]	Raterman HG, Bultink IE, Lems WF. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiolo-gy, pathogenesis, and fracture prevention[J]. Expert Opin Pharmacother, 2020, 21:1725-1737.
[4]	Wang D, Cai G, Wang H, et al. TRAF3, a target of microRNA-363-3p, suppresses senescence and regulates the balance between osteoblastic and adipocytic differentiation of rat bone marrow-derived mesenchymal stem cells[J]. Stem Cells Dev,2020, 29:737-745.
[5]	Del Real A, López-Delgado L, Saóudo C, et al. Long noncoding RNAs as bone marrow stem cell regulators in osteoporosis[J]. DNA Cell Biol, 2020, 39:1691-1699.
[6]	Wang CG, Hu YH, Su SL, et al. LncRNA DANCR and miR-320a suppressed osteogenic differentiation in osteoporosis by directly inhibiting the Wnt/β-catenin signaling pathway[J]. Exp Mol Med, 2020, 52:1310-1325.
[7]	Teng Z, Zhu Y, Zhang X, et al. Osteoporosis is characterized by altered expression of exosomal long non-coding RNAs[J]. Front Genet, 2020, 11:566959-566972.
[8]	Kou J, Zheng X, Guo J, et al. MicroRNA-218-5p relieves postmenopausal osteoporosis through promoting the osteoblast differentiation of bone marrow mesenchymal stem cells[J]. J Cell Biochem, 2020, 121:1216-1226.
[9]	Ko NY, Chen LR, Chen KH. The role of microRNA and long-non-coding RNA in osteoporosis[J]. Int J Mol Sci,2020, 21:4886-4903.
[10]	范琳媛, 李红凌. 长链非编码RNAs调控骨稳态研究进展[J]. 基础医学与临床, 2020, 40: 115-119.
[11]	Li Z, Hong Z, Zheng Y, et al. An emerging potential therapeutic target for osteoporosis: lncRNA H19/miR-29a-3p axis[J]. Eur J Histochem, 2020, 64:3155-3160.
[12]	Feng J, Wang JX, Li CH. LncRNA GAS5 over-expression alleviates the development of osteoporosis through promot-ing osteogenic differentiation of MSCs via targeting microRNA-498 to regulate RUNX2[J]. Eur Rev Med Pharmacol Sci, 2019, 23:7757-7765.
[13]	Xie W, Li F, Han Y, et al. Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP/PKA/CREB pathway[J]. Aging (Albany NY),2020, 12:8120-8136.